Article · Wikipedia archive · Last revised Jun 19, 2026

6-MAPB

6-MAPB is an entactogen of the benzofuran family which is structurally related to 6-APB and MDMA. It is known to be a serotonin releasing agent and, unlike MDMA, a potent serotonin 5-HT1B receptor agonist. The drug is not known to have been widely sold as a "designer drug" but has been detected in analytical samples taken from individuals hospitalised after using drug combinations that included other benzofuran derivatives. 6-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014. It was banned in the United Kingdom in June 2013, along with 9 other related compounds which were thought to produce similar effects.

Last revised
Jun 19, 2026
Read time
≈ 2 min
Length
437 w
Citations
11
Source
Wikipedia ↗
6-MAPB
Clinical data
Other names1-(Benzofuran-6-yl)-N-methylpropan-2-amine
Routes of
administration		Oral1
Drug classMonoamine releasing agent; Serotonin 5-HT1B receptor agonist
Legal status
Legal status
Pharmacokinetic data
Duration of action6–8 hours1
Identifiers
  • 1-(Benzofuran-6-yl)-N-methylpropan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H15NO
Molar mass189.258 g·mol−1
3D model (JSmol)
  • CC(NC)CC1=CC(OC=C2)=C2C=C1
  • InChI=1S/C12H15NO/c1-9(13-2)7-10-3-4-11-5-6-14-12(11)8-10/h3-6,8-9,13H,7H2,1-2H3
  • Key:QLAAURQYEAEHBO-UHFFFAOYSA-N

6-MAPB (1-(benzofuran-6-yl)-N-methylpropan-2-amine) is an entactogen of the benzofuran family which is structurally related to 6-APB and MDMA.12345 It is known to be a serotonin releasing agent and, unlike MDMA, a potent serotonin 5-HT1B receptor agonist.6 The drug is not known to have been widely sold as a "designer drug" but has been detected in analytical samples taken from individuals hospitalised after using drug combinations that included other benzofuran derivatives. 6-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014.78 It was banned in the United Kingdom in June 2013, along with 9 other related compounds which were thought to produce similar effects.9

Interactions

See also

See also

References

References

  1. Oeri HE (May 2021). "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". J Psychopharmacol. 35 (5): 512–536. doi:10.1177/0269881120920420. PMC 8155739. PMID 32909493.
  2. Welter J, Brandt SD, Kavanagh P, Meyer MR, Maurer HH (May 2015). "Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MS(n) techniques" (PDF). Analytical and Bioanalytical Chemistry. 407 (12): 3457–3470. doi:10.1007/s00216-015-8552-2. PMID 25711990. S2CID 5475974.
  3. Welter-Luedeke J, Maurer HH (February 2016). "New Psychoactive Substances: Chemistry, Pharmacology, Metabolism, and Detectability of Amphetamine Derivatives With Modified Ring Systems". Therapeutic Drug Monitoring. 38 (1): 4–11. doi:10.1097/FTD.0000000000000240. PMID 26327309. S2CID 20737913.
  4. Shimshoni JA, Winkler I, Golan E, Nutt D (January 2017). "Neurochemical binding profiles of novel indole and benzofuran MDMA analogues". Naunyn-Schmiedeberg's Archives of Pharmacology. 390 (1): 15–24. doi:10.1007/s00210-016-1297-4. hdl:10044/1/43622. PMID 27650729. S2CID 253741131.
  5. Brandt SD, Walters HM, Partilla JS, Blough BE, Kavanagh PV, Baumann MH (December 2020). "The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats". Psychopharmacology. 237 (12): 3703–3714. doi:10.1007/s00213-020-05648-z. PMC 7686291. PMID 32875347.
  6. US 20230150963, Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", published 2023 May 18, assigned to Tactogen 
  7. King LA (2014). "New phenethylamines in Europe". Drug Test Anal. 6 (7–8): 808–818. doi:10.1002/dta.1570. PMID 24574327.
  8. EMCDDA–Europol 2013 Annual Report on the implementation of Council Decision 2005/387/JHA
  9. "Temporary class drug order report on 5-6APB and NBOMe compounds". UK Home Office. 4 Jun 2013. Retrieved 2013-07-10.
External links